Literature DB >> 21686467

Anticonvulsant hypersensitivity syndrome closely mimicking Kawasaki disease.

Elpis Mantadakis1, Aggelos Tsalkidis, Emmanouel Paraskakis, Kyriaki Papadopoulou-Legbelou, George Varlamis, Athanassios Evangeliou, Athanassios Chatzimichael.   

Abstract

Anticonvulsant hypersensitivity syndrome (AHS) is an acute, life-threatening, idiosyncratic drug reaction seen within 1-8 weeks after administration of an aromatic antiepileptic drug. The authors present the case of a 16-month-old boy who developed prolonged fever, a generalised pruritic rash and eosinophilia within 4 weeks after starting treatment with phenobarbital for complicated febrile seizures. He gradually fulfilled the diagnostic criteria for classical Kawasaki disease (KD), although the rash and the subsequent desquamation were atypical, he did not defervesce quickly with administration of corticosteroids and intravenous γ-globulin, and he had only two suggestive cardiac features of KD-that is, perivascular echogenicity of the coronary arteries and a small pericardial effusion. Other conditions considered in the differential diagnosis were excluded by appropriate extensive serological and microbiological studies. He recovered fully. This report shows that drugs such as phenobarbital may be responsible for febrile exanthematous illnesses that closely mimic KD.

Entities:  

Year:  2009        PMID: 21686467      PMCID: PMC3029029          DOI: 10.1136/bcr.10.2008.1076

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Anticonvulsant hypersensitivity syndrome vs Kawasaki disease: a challenging clinical diagnosis with therapeutic implications.

Authors:  J Chinen; S Piecuch
Journal:  Clin Pediatr (Phila)       Date:  2000-02       Impact factor: 1.168

Review 2.  Superantigens, conventional antigens and the etiology of Kawasaki syndrome.

Authors:  H C Meissner; D Y Leung
Journal:  Pediatr Infect Dis J       Date:  2000-02       Impact factor: 2.129

3.  [The drug hypersensitivity syndrome or DRESS syndrome to phenobarbital].

Authors:  T Lachgar; Y Touil
Journal:  Allerg Immunol (Paris)       Date:  2001-04

Review 4.  Anticonvulsant hypersensitivity syndrome: incidence, prevention and management.

Authors:  S R Knowles; L E Shapiro; N H Shear
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

5.  Kawasaki-like syndrome caused by carbamazepine.

Authors:  R A Hicks; J V Murphy; M A Jackson
Journal:  Pediatr Infect Dis J       Date:  1988-07       Impact factor: 2.129

6.  [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

Authors:  T Kawasaki
Journal:  Arerugi       Date:  1967-03

7.  Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  Jane W Newburger; Masato Takahashi; Michael A Gerber; Michael H Gewitz; Lloyd Y Tani; Jane C Burns; Stanford T Shulman; Ann F Bolger; Patricia Ferrieri; Robert S Baltimore; Walter R Wilson; Larry M Baddour; Matthew E Levison; Thomas J Pallasch; Donald A Falace; Kathryn A Taubert
Journal:  Pediatrics       Date:  2004-12       Impact factor: 7.124

Review 8.  Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care.

Authors:  KarenBeth H Bohan; Tarannum F Mansuri; Natalie M Wilson
Journal:  Pharmacotherapy       Date:  2007-10       Impact factor: 4.705

9.  Anticonvulsant hypersensitivity syndrome: lymphocyte toxicity assay for the confirmation of diagnosis and risk assessment.

Authors:  Sandeep B Bavdekar; Mamta N Muranjan; Nithya J Gogtay; Vishakha Kantharia; Nilima A Kshirsagar
Journal:  Ann Pharmacother       Date:  2004-08-10       Impact factor: 3.154

10.  The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease.

Authors:  Ho-Chang Kuo; Kuender D Yang; Chi-Di Liang; Chin-Nam Bong; Hong-Ren Yu; Lin Wang; Chih-Lu Wang
Journal:  Pediatr Allergy Immunol       Date:  2007-06       Impact factor: 6.377

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.